1 reply to this topic

[caliban]

Migenix (MGI - Toronto)

Research focussed on programs in the areas of infectious diseases and degenerative diseases .
Currently has five compounds in clinical development: MX-3253 (celgosivir) antiviral agent under development for the treatment of chronic Hepatitis C Virus (HCV) infection. MX-4509 is an orally administered sodium salt of 17á-estradiol 3-sulphate under development for the treatment of mild to moderate Alzheimer’s disease. MX-226 a antibiotic for the prevention of catheter-related infections.
MX-594AN antibiotic for the treatment of acne. MX-1121 antisense oligonucleotide drug in clinical development for the treatment of diseases associated with Human Papillomavirus (HPV) such as genital warts

http://www.migenix.com/

[caliban]

They aquired MitoKor (formerly Applied Genetics) in 2004 which was studying mitochondrial therapies.

MitoKor didn't really have a product and was running out of money. They were lead into the merger by CEO Walter Moos, a savy and experienced promoter who's now on the board of Migenix.

Here is an article on MitoKor and how the takeover was arranged (no mention of Migenix yet) -> http://www.biospace....les/mitokor.cfm